Dewpoint translates biomolecular condensate biology into therapeutics. Its proprietary platform is designed to identify condensate targets and to discover and optimize small molecule condensate modulators, or c-mods, a new drug modality with novel mechanisms of action. The company is advancing a diversified portfolio across multiple disease areas of high unmet need, spanning early discovery to clinical stage programs.
$1.1B
Combined potential deal value
Across the Bayer and Novo Nordisk collaborations, which provide validation and acceleration for the condensate platform.
1st
First-in-class c-mod in the clinic
DPTX3186 is under Phase Ia/IIa investigation with FDA fast track and orphan drug designations. The first patient was dosed in early 2026.
4
Therapeutic areas in the pipeline
Oncology, neurodegeneration, cardiopulmonary and metabolic disease, spanning wholly owned and partnered programs.
Platform
Dewpoint's platform is built around biomolecular condensate biology, which studies the organization of proteins and RNA in dynamic, membrane-less cellular compartments formed via phase separation. This is a novel understanding of how biological processes are regulated in health and disease.
The company's operating thesis is that disease-associated condensate dysfunction creates actionable therapeutic opportunities across therapeutic areas, including complex diseases of high unmet need previously thought to be intractable.
Dewpoint's pipeline is powered by ERSAi, a proprietary AI-enabled end-to-end discovery platform used to identify condensate targets, and to discover, optimize and translate c-mods.
Pipeline
Dewpoint's multi-therapeutic area pipeline consists of programs that span oncology, neurodegeneration, cardiopulmonary and metabolic diseases.
Wholly owned programs
DPTX3186 is the company's first clinical development candidate, a first-in-class c-mod with fast track and orphan drug FDA designations, currently under Phase Ia/IIa clinical investigation for gastric cancer.
Preclinical internal programs include MYC-driven solid cancers and ALS.
Partnered programs
Dewpoint has ongoing early discovery programs in the cardiopulmonary therapeutic area in partnership with Bayer, and in the metabolic disease and insulin resistance area with Novo Nordisk.
| Program | Target | Indication | Stage | Ownership |
|---|---|---|---|---|
| DPTX3186 | Beta-catenin | Gastric cancer, advanced solid tumors | Phase Ia/IIa | Wholly owned |
| MYC program | MYC | MYC-driven solid tumors | Development candidate | Wholly owned |
| TDP-43 program | TDP-43 | ALS | Development candidate | Wholly owned |
| Cardiopulmonary | Undisclosed | Cardiopulmonary disease | Early discovery | Partnered with Bayer |
| Metabolic | Undisclosed | Insulin resistance | Early discovery | Partnered with Novo Nordisk |
Key Milestones
01
DPTX3186, a first-in-class c-mod, has entered the clinic with FDA orphan drug and fast track designations. It is currently under Phase Ia/IIa clinical investigation for gastric cancer, and the first patient was dosed in early 2026.
02
A development candidate for the MYC-driven solid tumors program announced.
03
A development candidate for the ALS program announced.
Intellectual Property
Dewpoint has established a strong and growing intellectual property estate that includes robust patent protections covering its platform technology, as well as key composition of matter patents directed to its development candidates.
Most notably, the composition of matter patent for DPTX3186 issued in 2026, representing a significant milestone for the program and the company. Dewpoint continues to actively assess areas of expansion for its patent portfolio to strengthen its intellectual property position.
Funding and Strategic Partnerships
The company has financed the business through early clinical proof of concept via Series A to D venture rounds.
Dewpoint has partnered with large pharmaceutical companies including Bayer and Novo Nordisk. These partnerships provide validation and acceleration of Dewpoint's platform, with a combined potential deal value of $1.1B.
Strengths:
Proprietary AI and machine learning integrated platform technology, ERSAi, supports the four pillars of Dewpoint's condensate-targeted R&D approach, from target discovery to drug discovery, optimization and development
Robust patent portfolio, including technology and composition of matter
Diversified pipeline of wholly owned and partnered programs
Validated path to clinic for the first c-mod asset and two development candidates in the pipeline
Partner of choice for condensate-targeted drug discovery
Considerations:
Pre-commercial state, with financial reliance on investments and strategic partnerships
Early clinical stage, on path to clinical proof of concept
Opportunities:
Novel approach to drug discovery via condensate targets is relevant, applicable and readily translatable to a broad range of disease areas, including complex diseases
Market Context:
First mover advantage with a new mechanistic drug modality that is yet to be validated clinically
The Pharma Letter View
Condensate biology has been one of the more attractive ideas in drug discovery since Anthony Hyman and Richard Young helped define the field. The harder question has always been whether a small molecule built on that thesis could reach a patient. In February 2026 Dewpoint answered it, dosing the first patient with DPTX3186 under fast track and orphan drug designations.
What follows is the harder part. Beta-catenin and MYC are targets the industry has circled for decades without a durable answer, and a first-in-human dose escalation will not by itself settle whether condensate modulation succeeds where conventional chemistry did not. Dewpoint has stacked the odds sensibly: two further development candidates selected in 2026, an IP estate the company says is now anchored by a composition of matter patent on its lead, and collaborations with Bayer and Novo Nordisk that Dewpoint puts at a combined potential value of $1.1B.
For readers, the signal to watch is not the platform narrative, which is well made and by now familiar. It is whether the first clinical data support the mechanism, and whether the MYC and TDP-43 candidates convert selection into INDs on the timeline the company has set.
Senior Leadership Team
The senior leadership team at Dewpoint has collective experience in big pharma, biotech, clinical care and academia, across condensate biology, AI and machine learning, scientific translation and clinical development. The founder group includes Anthony Hyman, PhD, Richard Young, PhD, and Phillip Sharp, PhD, senior academic scientists associated with founding and developing the condensate biology field.
Ameet Nathwani, MD
Chief Executive Officer
A physician and global drug developer with more than 25 years in the biopharmaceutical industry. He joined Dewpoint from Sanofi, where he sat on the executive committee as Chief Medical Officer and Chief Digital Officer. Before that he spent over a decade at Novartis Pharma, including as Global Head of Medical Affairs and, earlier, Global Development Head for its cardiovascular and metabolism franchise. He began his industry career in R&D at GlaxoSmithKline and SmithKline Beecham.
Isaac Klein, MD, PhD
Chief Development and Operating Officer
A physician-scientist and medical oncologist who has studied the intersection of condensate science, cell biology and disease. He joined from the Dana-Farber Cancer Institute and Harvard Medical School, where he was on faculty, and from the Whitehead Institute at MIT, where he helped establish the role of condensates in gene control and oncogenesis. He has authored more than 30 publications and holds multiple patents.
Ann Boija, PhD
Chief Scientific Officer
Leads research at Dewpoint across oncology, neurology, cardiology and metabolic disease. Her work helped uncover how phase separation of transcription factors regulates gene expression, and how anti-cancer drugs partition into condensates, findings that opened therapeutic possibilities for previously inaccessible targets. She holds a PhD in biology from Stockholm University and completed postdoctoral training at the Whitehead Institute at MIT.
Heather Hamel, JD
General Counsel and Head of Corporate Affairs
Leads Dewpoint's legal function, covering corporate governance, intellectual property strategy and operations, data privacy, employment, financing and partnering support. She was previously General Counsel and Chief Legal Officer of InVivo Therapeutics, and before that held intellectual property roles at Ecolab and PLR IP. She began her career as a biomaterials research associate at the University of Wisconsin.
Francis Carpenter, PhD
SVP, Head of Technology and Corporate Strategy
Works at the intersection of data science, product and strategy, and leads the scaling of the data-led approaches behind Dewpoint's discovery and clinical translation work. He joined from McKinsey and QuantumBlack, where as an associate partner he led teams applying AI to biopharma R&D. Earlier he was a principal product manager at Genomics England.